This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Successfully Balancing The Needs of The Planet With The Needs of The Patient
Publications, Pharmaceutical, Product Solutions, Sustainability, Innovation & Insights, Device Innovations
Using digital healthcare to improve patient compliance and adherence
Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions
Introducing PureHale® for targeted upper respiratory tract care
Webinars, Pharmaceutical, Product Solutions, Device Innovations, Brand Differentiation, Market Insights
Aptar Pharma talks targeted drug delivery to the upper airways
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation
